Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Atorvastatin and Sympathetic Activity in Chronic Kidney Disease

This study has been completed.
Information provided by:
UMC Utrecht Identifier:
First received: December 8, 2010
Last updated: NA
Last verified: November 2010
History: No changes posted

Hypertensive chronic kidney disease (CKD) patients often have sympathetic hyperactivity which appears to contribute to the pathogenesis of hypertension and cardiovascular organ damage. Experimental studies and some clinical studies have shown that statin therapy can reduce central sympathetic activity. Blockade of the renin-angiotensin system (RAS), which is standard treatment for CKD, is known to lower sympathetic activity.

The investigators hypothesize that adding a statin for 6 weeks to RAS blockade would further lower sympathetic activity in hypertensive stage 2-4 CKD patients.

Methods: In ten stable CKD patients who are on chronic treatment with renin-angiotenis blockers, blood pressure and sympathetic activity (quantified by assessment of muscle sympathetic nerve activity, MSNA) will be assessed at baseline and 6 weeks after atorvastatin 20mg/day added.

Ten other CKD patients will serve as time control and will be studied twice with an interval of 6 weeks without any change in medication, to quantify within subject reproducibility.

Condition Intervention Phase
Stable Chronic Kidney Disease
Drug: Atorvastatin
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Atorvastatin Reduces Sympathetic Activity in Patients With Chronic Kidney Disease

Resource links provided by NLM:

Further study details as provided by UMC Utrecht:

Primary Outcome Measures:
  • Sympathetic activity [ Time Frame: 4-6 weeks treatment ]

Estimated Enrollment: 10
Study Start Date: August 2009
Study Completion Date: July 2010
Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Arm 1: cessation of any statin therapy for at least 6 weeks, then the first sympathetic activity measurement will be done.Subsequently, atorvastatin 20mg is added for 6 weeks. Then the second sympathetic measurement will be performed.
Drug: Atorvastatin
6 weeks treatment with atorvastatin and studying the effect of atorvastatin on sympathetic activity
Other Name: Lipitor
Patients will receive atorvastatin for 6 weeks, then the first sympathetic measurement will be done. Then atorvastatin will be stopped and 6 weeks the second measurement will be done
Drug: Atorvastatin
6 weeks treatment with atorvastatin and studying the effect of atorvastatin on sympathetic activity
Other Name: Lipitor

Detailed Description:
see above

Ages Eligible for Study:   18 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • stable chronic kidney disease
  • Hypertension

Exclusion Criteria:

  • renal replacement therapy
  • pregnancy
  • diabetes mellitus
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01257009

University Medical Center utrecht
Utrecht, Netherlands, 3584CX
Sponsors and Collaborators
UMC Utrecht
  More Information Identifier: NCT01257009     History of Changes
Other Study ID Numbers: Statin sympathetic
Study First Received: December 8, 2010
Last Updated: December 8, 2010

Keywords provided by UMC Utrecht:
sympathetic activity
chronic kidney disease

Additional relevant MeSH terms:
Renal Insufficiency, Chronic
Kidney Diseases
Renal Insufficiency
Urologic Diseases
Atorvastatin Calcium
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors processed this record on May 25, 2017